Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs)

Vaccine

Volumn 17, Issue 13-14, 1999, Pages 1782-1787

  Glück, Reinhard ^a  

^a Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXOID; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; MEMBRANE PHOSPHOLIPID; NUCLEIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID ANTIBODY; TETANUS TOXOID; VIRUS GLYCOPROTEIN;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG FORMULATION; HEPATITIS A VIRUS; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOPOTENTIATION; INFLUENZA VIRUS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; NORMAL HUMAN; PRIORITY JOURNAL; VIRION;

ADJUVANTS, IMMUNOLOGIC; HEPATITIS A VACCINES; HUMANS; INFLUENZA VACCINES; LIPOSOMES; ORTHOMYXOVIRIDAE; VIRAL HEPATITIS VACCINES;

EID: 0038439355     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00440-X     Document Type: Conference Paper

References (29)

1. Allison A.C., Gregoriadis G. Liposomes as immunological adjuvants. Nature. 252:1974;252-255.
2. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol. Today. 11:1990;89-97.
3. Glück R. Combined vaccines: the European contribution. Biologicals. 22:1994;347-351.
4. Glück R., Mischler R., Brantschen S., Just M., Althaus B., Cryz S.J. Jr. Immunopotentiating reconstituted influenza virosome (IRIV) vaccine delivery system for immunization against hepatitis A. J. Clin. Invest. 90:1992;2491-2495.
5. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. TIBTECH. 13:1995;527-537.
6. Seganti L., Superti F., Orsini N., Gabrielli R., Divizia M., Panà A. Membrane lipid components interacting with hepatitis A virus. Microbiologica. 12:1989;225-230.
7. Garçon N.M., Six H.R. Universal vaccine carrier: liposomes that provide T-dependent help to weak antigen. J. Immunol. 146(11):1991;3697-3702.
8. Tsurudome M., Glück R., Graf R., Falchetto R., Schaller U., Brunner J. Lipid interactions of the hemagglutinin HA2NH2-terminal segment during influenza virus-induced membrane fusion. J. Biol. Chem. 267(28):1992;20225-20232.
9. +-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region. J. Biol. Chem. 271(23):1996;13417-13421.
10. Matlin K.S., Reggio H., Helenius A., Simmons K. Infections entry pathway of influenza virus in a canine kidney cell line. J. Cell. Biol. 91:1981;601-613.
11. Glück R. Liposomal presentation of antigens for human vaccines. In: Powell M.R., Newman M.J., editors. Vaccine design. New York and London: Plenum Press, 1995. p. 325-45.
12. Rott O., Charreire J., Mignon-Godefroy K., Cash E. B-cell superstimulatory influenza virus activates peritoneal B-cells. J. Immunol. 155:1995;134-142.
13. 2+-independent mechanism. J. Immunol. 154:1995;2092-2103.
14. Parker E.E., Gould K.G. Influenza A virus: a model for viral antigen presentation to cytotoxic T-lymphocytes. Virology. 7:1996;61-73.
15. Air G.M., Laver W.G. The neuraminidase of influenza virus. Proteins. 6:1989;341-356.
16. Muster T., Ferko B., Klima A., Purtscher M., Trkola A., Schulz P., Grassauer K., Engelhardt O.G., Garcia-Sastre A., Palese P., Katinger H. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J. Virol. 69(11):1995;6678-6686.
17. Mengiardi B. Virosomen als Träger von Kombinationsimpfstoffen. Inauguraldissertation, Universitätskinderklinik Basel, Mediz. Fakultät der Universität Basel, 1994.
18. Mengiardi B., Berger R., Just M., Glück R. Virosomes as carriers for combined vaccines. Vaccine. 13:1995;1306-1315.
19. Glück R. Towards a universal IRIV traveller vaccine. In: Third Conference on International Travel Medicine, Paris, France, 25-29, April 1993, Abstract No. 259, 1993.
20. Just M. Experience with IRIV as carrier for hepatitis A and other antigens. In: Third Conference on International Travel Medicine, Paris, 25-29 April 1993, Abstract No. 277, 1993.
21. Glück R., Mischler R., Finkel B.et al. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344:1994;160-163.
22. Conne P., Gauthey L., Vernet P., Althaus B., Que J.U., Finkel B., Glück R., Cryz S.J. Jr. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine. 15(15):1997;1675-1679.
23. Cryz S.J., Que J.U., Glück R. A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antibody response in humans. Vaccine. 14:1996;1381-1383.
24. Lea A.P., Balfour J.A. Virosomal hepatitis A vaccine (strain RG-SB): a preliminary review of its immunogenicity protective efficacy and tolerability in at-risk populations. BioDrug. 7:1997;232-248.
25. Bovier P., Loutan L., Farinelli T., Herzog C., Glück R. Cross-immunogenicity and tolerance of two inactivated vaccines against hepatitis A virus. In: European Conference of Tropical Medicine, 22-26 October 1995, Hamburg (C41).
26. Holzer B.R., Hatz C., Schmidt-Sissolak D., Glück R., Althaus B., Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine. 14(10):1996;982-986.
27. Poovorawan Y., Theamboonlers A., Chumdermpadetsuk S., Glück R., Cryz S.J. Jr. Safety, immunogenicity and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine. 13(10):1995;891-893.
28. Poovorawan Y., Tieamboonlers A., Chumdermpadetsuk S., Glück R., Cryz S.J. Control of a hepatitis A outbreak by active immunization of high-risk susceptibles subjects. J. Infect. Dis. 169:1994;228-229. (Letter to the Editor).
29. Glück R. Liposomal hepatitis A vaccine and liposomal multiantigen combination vaccines. J. Liposome Res. 5(3):1995;467-479.